LONDON (Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has selected a drug candidate from the Orexin-1 programme to enter pre-clinical development ahead of the initiation of clinical studies for the treatment of stress-related addictive disorders.
In addition to this drug candidate, C4X is working on progressing additional series of Orexin-1 inhibitors with distinct profiles to enable the development of follow-up compounds for other indications within the field of addiction treatment.
C4X expects the candidate to begin clinical development in the second half of 2016.
"We are enormously excited by this significant demonstration of the power of our technology. Taking our proprietary drug candidate into preclinical development represents an important milestone," said Chief Executive Piers Morgan.
Shares in C4X were up 1.8% to 85.00 pence on Wednesday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.